LTR Pharma (ASX:LTP) has executed a definitive Compounding and Supply Agreement with Strive Specialties Inc (“Strive Pharmacy”), converting a previously announced binding Term Sheet into a comprehensive long-form commercial agreement. Announced on 20 July 2026, the deal covers the planned manufacturing, compounding, fulfilment and nationwide supply of ROXUS® across the United States.
The agreement completes the second of two core commercial pillars required for U.S. launch, sitting alongside the previously announced Shed telehealth agreement. With both definitive agreements now in place, LTR Pharma has signalled that its focus shifts from partner selection to implementation and Commercial Launch.
The two pillars now in place for U.S. commercial launch
LTR Pharma’s U.S. strategy rests on a two-pillar model. The first pillar covers patient acquisition and prescribing, delivered through the Shed telehealth agreement and independent clinics. The second pillar covers national manufacturing and fulfilment, now secured through the Strive Pharmacy agreement.
With both definitive agreements executed, the operational foundation for a U.S. launch of the intranasal erectile dysfunction treatment is complete. The framework governs manufacturing, quality systems, API sourcing, product change control, fulfilment and supply-chain management as both companies prepare for launch.
The Shed agreement carries a 150,000-unit first-year commitment, with that volume threshold underpinning Shed’s two-year direct-to-consumer exclusivity and providing a quantified demand baseline for Strive Pharmacy’s manufacturing and fulfilment planning.
Lee Rodne, Executive Chairman, LTR Pharma
“Executing the definitive agreement with Strive Pharmacy completes another major piece of our U.S. commercialisation strategy. While Shed provides patient acquisition and telehealth capability, Strive Pharmacy provides the national manufacturing, compounding and fulfilment infrastructure required to supply ROXUS across the United States. With both definitive agreements now in place, our focus shifts from partner selection to implementation and Commercial Launch. We believe this significantly strengthens our U.S. execution pathway and reduces commercial risk.”
The table below summarises how responsibilities are divided across the U.S. commercialisation model.
| Role | Partner / Entity | Responsibility |
|---|---|---|
| Product owner | LTR Pharma | Owns the product |
| Prescribing / acquisition | Shed Telehealth + Independent Clinics | Prescribes to the patient, direct-to-consumer |
| Manufacturing / fulfilment | Strive Pharmacy | Manufacture, compound, fulfil |
| End recipient | U.S. Patient | Receives the treatment |
When big ASX news breaks, our subscribers know first
Inside the Strive Pharmacy partnership
Strive Pharmacy operates an established Section 503A compounding pharmacy platform across five U.S. states, with licensure supporting nationwide compounding, packaging, fulfilment and shipping of prescription treatments. The company supports prescribers, clinics and telehealth providers through its fulfilment infrastructure and established provider network.
Through this partnership, LTR Pharma gains access to an established national compounding pharmacy with the infrastructure, regulatory systems and fulfilment capability to support Commercial Launch and future growth across its U.S. commercial channels.
The agreement establishes the operational framework covering:
-
Technology transfer
-
Manufacturing and quality systems
-
API procurement and sourcing
-
Inventory management
-
Nationwide prescription fulfilment
Strive Pharmacy President and Co-Founder Michael Walker described ROXUS as “a highly differentiated product,” adding that the company looks forward to supporting its U.S. launch through Strive Pharmacy’s national compounding, manufacturing and fulfilment capabilities.
What is Section 503A compounding, and why it matters for investors
A Section 503A compounding pharmacy is a U.S.-based personalised medicine and compounding pharmacy operating an established multi-state platform, with licensure supporting nationwide compounding, packaging, fulfilment and shipping of prescription treatments.
For LTR Pharma, this route provides a pathway to supply ROXUS across the United States through telehealth and clinic channels, using an existing multi-state platform. It allows the intranasal treatment to reach patients while the Company continues to advance broader regulatory pathways in the U.S. and other key markets.
Next steps toward Commercial Launch
LTR Pharma and Strive Pharmacy will now focus on the operational work required ahead of launch. Management believes the combination of Shed’s patient acquisition capability and Strive Pharmacy’s manufacturing and fulfilment platform provides a scalable operational foundation for the U.S. commercialisation of ROXUS.
The near-term focus areas include:
-
Technology transfer
-
Commercial inventory planning
-
Manufacturing readiness
-
Operational implementation ahead of Commercial Launch
No specific launch date has been disclosed. The Company has stated it will continue to update shareholders as key Commercial Launch milestones are achieved.
For readers interested in how far the intranasal platform extends beyond erectile dysfunction, our dedicated guide to OROFLOW and the oesophageal motility disorder program covers the ethics approval milestone, the clinical study design targeting achalasia and related conditions, and the US$8.1 billion market opportunity LTR Pharma is pursuing with its third product candidate.
LTR Pharma is a commercial-stage pharmaceutical company operating a proprietary intranasal drug-delivery platform. Its lead products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. The Company is also advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders, a group of conditions affecting swallowing function.
Don’t Miss the Next Healthcare Breakout on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to receive real-time alerts the moment market-moving healthcare announcements drop.